IMPACT Therapeutics, Inc. (H shares) filed its Monthly Return for the period ended 31 July 2026, confirming that the company’s equity structure remained unchanged during the month.

• Authorised and issued capital unchanged – Authorised share capital: 282.46 million H shares at RMB 1 par value, totalling RMB 282.46 million. – Issued shares: 282.46 million; treasury shares: zero. No new shares were issued, cancelled, or repurchased in July.

• Public float confirmation – The company certified that, as at 31 July 2026, it met the Main Board’s minimum 25% public float threshold for its H shares.

• No outstanding equity instruments – The report records no share options, warrants, convertibles, or other agreements that could dilute share capital.

The filing was signed by Executive Director and CEO Dr. Sui Xiong Cai and submitted to Hong Kong Exchanges and Clearing Limited on 5 August 2026.